Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a rare disease characterized by a rapidly fatal hematological disorder usually associated with malignancies and severe infections. It presents with prolonged high fever that could not be controlled by antibiotics; hepatosplenomegaly; cytopenia; widespread infiltration with lymphocytes; and benignlooking histiocytes with hemophagocytosis in the bone marrow, liver, spleen, or lymph nodes. A steadily increasing attention has been paid to HLH in the past decade. Early diagnosis and combined treatment can effectively control this life-threatening disease. In this study, we have described the progression of 56 children with HLH who underwent treatment in Wuhan Union Hospital, People's Republic of China, and have emphasized the prognostic factors in an effort to improve the outcome of patients with HLH.
Methods

Diagnosis and patients
A retrospective analysis on HLH was carried out from January 1, 2000 
Results
clinical features
Of the 56 pediatric patients, 35 were boys and 21 were girls with a median age of 4.5 years (range: 4 months to 12 years) at the onset of HLH. The median duration before diagnosis of HLH was 1.5 weeks (range: 1 week to 6 weeks). The most common clinical symptoms observed were fever (100.00%), hepatomegaly or splenomegaly (95.24%), and pancytopenia (100.0%). The clinical features observed in the patients are shown in Figure 1 .
Laboratory findings
The laboratory results obtained for all pediatric patients with HLH are given in Table 1 . Anemia was observed in 39 patients (five cases with hemoglobin level <90 g/L, 27 cases <60-89 g/L, seven cases <30-59 g/L), neutropenia (neutrophil count <1.5×10 
associated underlying diseases
Infectious agents were identified in 35 (61.90%) patients. Non-infectious agents of HLH were identified in six (10.70%) patients. No agents were identified in the remaining 15 cases (26.78%). Analysis of etiology is shown in Figure 2 .
Treatment and outcome
Forty-two patients were treated according to the HLH-94 or HLH-2004 guidelines; 14 patients refused treatment and lost follow-up because of rapid fatality or financial difficulty and belief of HLH incurability. The common supportive treatments included packed red cell, fresh plasma, and platelet transfusions. Those patients who underwent treatment received steroid and intravenous immunoglobulin. Of the 42 treated patients, 25 acquired remission and 17 died of relapse. 4 and acquired immune deficiency states. [5] [6] [7] Thirty-one patients were found to have secondary HLH. Epstein-Barr virus is the main viral infectious agent, which accounted for 19.05% of the infections. In our study, hematological malignancies were the second conditions (9.52%) associated with HLH, in lower proportion than previous reports. 8, 9 The onset characteristic of HLH is complicated by common clinical and laboratory findings that may present in other infectious disease, such as pneumonia or sepsis. The patients' condition became worse rapidly. Early recognition of HLH and immediate appropriate therapy to HLH patients have been identified to improve or to relieve the disease progression. The time from the onset of symptoms to the diagnosis varied from 1 to 6 weeks (median 1.5 weeks) in our patients. The delay of diagnosis or prolonged duration of diagnosis (1.5 weeks) reflected the difficulties in diagnosing HLH. Persistent fever, hepatosplenomegaly, cytopenia, hypertriglyceridemia, and/or hypofibrinogenemia, together with the progressive course, suggest suspicion of an HLH diagnosis and the pediatricians should be aware of the hemophagocytosis in bone marrow. 10 gupta et al 11 reported that the sensitivity is 60% for hemophagocytosis in initial bone marrow aspirate in patients diagnosed with HLH. Of the 56 patients with HLH, hemophagocytosis was not found in six patients. so repeated bone marrow aspiration was recommended to these patients. Physicians should note the fact that cytological characteristic of hemophagocytosis is not the gold standard for the diagnosis 
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Wang et al of HLH. some potential prognostic factors, such as cytokine levels, may reveal a consistent elevation in HLH patients. It was reported that a cytokine storm occurred in most of the HLH patients, which was responsible for the clinical manifestations and abnormal laboratory data of HLH. [12] [13] [14] High levels of LDH and bilirubin accompanied with younger age were observed in our patients which may predict the severity of HLH. Further investigations should focus on identify the result.
Previous studies of HLH indicated that older age (in adults), multidrug chemotherapy, and Epstein-Barr virus reactivation were related to poor treatment outcomes in these patients. 15 According to the guideline of HLH (HLH-94) in children, the drugs such as dexamethasone, etoposide, cyclosporine A were employed (after 8 weeks) in combination with antithymocyte globulin/antilymphocyte globulin and high-dose intravenous immunoglobulin as systemic therapy. 16 Mild cases may require remission on condition that corticosteroids are used properly. Patients with primary HLH required Hematopoietic stem Cell Transplantation 17 and they were treated with the aforementioned drugs until a transplant could be performed. 18, 19 Etoposide can destroy infected antigen-presenting cells. Dexamethasone can penetrate into the cerebrospinal fluid. Cyclosporine A inhibits T-cell activation and is considered as valuable cytolytic corticosteroids. HLH-94 and HLH-2004 enrolled 26 cases in our study, one patient was presumed primary HLH and treated with maintenance treatment, followed by Hematopoietic stem Cell Transplantation. The event-free survival of the patient till the last follow-up was 5 years.
Conclusion
In conclusion, the etiology of HLH is complicated and early diagnosis is difficult. The level of LDH and bilirubin may predict the severity of HLH. Depending on the clinical presentation, individualized therapy is needed for different patients.
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